Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Cardiovascular and Metabolic Risk in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving First-Line BCR-ABL1 Tyrosine Kinase Inhibitors in the United States: Baseline and Six-Month Follow-up Results from a Prospective Real-World Observational Study

Michael J. Mauro, MD, Vivian G. Oehler, MD, James E. Thompson, MD, James K. McCloskey, MD, Michael C. Heinrich, MD, Shaker R. Dakhil, MD, Irene DeGutis, PharmD, David Tabano, PhD, Wasiulla Khan, PhD, Javid J. Moslehi, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-137613

Published: 2020

Journal Articles

Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)

Shyamala C. Navada, MD, Guillermo Garcia-Manero, MD, Ehab L. Atallah, MD, M. Nabeel Rajeh, MD, Jamile M. Shammo, MD, Elizabeth A. Griffiths, MD, Samer K. Khaled, MD, Shaker R. Dakhil, MD, David E. Young, MD, Rosalie Odchimar-Reissig, RN, Afoluso Ronnee Adesanya, MD, Patrick S. Zbyszewski, MBA, Richard C. Woodman, MD, Pierre Fenaux, MD PhD, Lewis R. Silverman, MD

Blood (2019) 134 (Supplement_1): 566.

https://doi.org/10.1182/blood-2019-131676

Published: 2019

Journal Articles

Management of Mucositis with the Use of Leucovorin As Adjunct to Pralatrexate in Treatment of Peripheral T-Cell Lymphomas (PTCL) — Results from a Prospective Multicenter Phase 2 Clinical Trial

Andrei R Shustov, MD, Michi M Shinohara, MD, Shaker R. Dakhil, MD, Gajanan Bhat, Jasmine M. Zain, MD

Blood (2018) 132 (Supplement 1): 2910.

https://doi.org/10.1182/blood-2018-99-119684

Published: 2018

Journal Articles

Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naïve & Relapsed (Rel)/Refractory (Ref) Patients

Shyamala C. Navada, MD, Guillermo Garcia-Manero, MD, Ehab L. Atallah, MD, M. Nabeel Rajeh, MD, Jamile M. Shammo, MD, Elizabeth A. Griffiths, MD, Samer K. Khaled, MD, Shaker R. Dakhil, MD, David E. Young, MD, Rosalie Odchimar-Reissig, RN, Naveen Pemmaraju, MD, Yesid Alvarado, MD, Maro N. Ohanian, DO, Rosmy B. John, MSN, Patrick S. Zbyszewski, MBA, Manoj Maniar, PhD, Michael E. Petrone, MD MPH, Steven M. Fruchtman, MD, Lewis R. Silverman, MD

Blood (2018) 132 (Supplement 1): 230.

https://doi.org/10.1182/blood-2018-99-119259

Published: 2018

Journal Articles

Multiple Myeloma On Top of Chronic Myelogenous Leukemia

Elie Chalhoub, MD, Joseph Meouchy, MD, Shaker R. Dakhil, MD

Blood (2012) 120 (21): 4457.

https://doi.org/10.1182/blood.V120.21.4457.4457

Published: 2012

Journal Articles

Differences in Outcomes in Males and Females with Diffuse Large B-Cell Lymphoma with Induction Rituximab and Follicular Lymphoma Treated with Maintenance Rituximab

Thomas M Habermann, MD, Fangxin Hong, PhD, Vicki A. Morrison, MD, Shaker R. Dakhil, MD, James K. Weick, MD, Stanley R. Frankel, MD, Randy D. Gascoyne, MD, Richard I Fisher, MD, Bruce D. Cheson, MD, Edie A. Weller, PhD, Brad S. Kahl, M.D., Bruce A. Peterson, MD, Howard S Hochster, MD, Sandra J. Horning, M.D.

Blood (2012) 120 (21): 3705.

https://doi.org/10.1182/blood.V120.21.3705.3705

Published: 2012

Journal Articles

Final Results of a Single Arm Phase III Multicenter, Open-Label Study of Rituximab Administered by Faster Infusion in Patients with Previously Untreated Diffuse Large-B Cell (DLBCL) or Follicular Non-Hodgkin's Lymphoma (FL)

Shaker R. Dakhil, MD, Robert Hermann, MD, Akiko Chai, MS, Deborah Hurst, MD, Gregg Fine, MD, Paul Richards, MD

Blood (2011) 118 (21): 2703.

https://doi.org/10.1182/blood.V118.21.2703.2703

Published: 2011

Journal Articles

A Randomized Comparison of Standard Weekly Epoetin Alfa to Every-3-Week Epoetin Alfa and Every-3-Week Darbepoetin Alfa: A Study of the Mayo Clinic Cancer Research Consortium (MCCRC).

David P Steensma, MD, Shaker R. Dakhil, MD, Paul J Novotny, MS, Jeff A Sloan, PhD, David B Johnson, MD, Daniel M Anderson, MD, Bassam I Mattar, MD, Dennis F Moore, Jr., MD, Daniel Nikcevich, MD, PhD, Charles L Loprinzi, MD

Blood (2009) 114 (22): 3008.

https://doi.org/10.1182/blood.V114.22.3008.3008

Published: 2009

Journal Articles

A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation On the Erythropoietic Response to Darbepoetin Alfa for Patients with Chemotherapy-Associated Anemia: A Study of the Mayo Clinic Cancer Research Consortium (MCCRC).

David P Steensma, MD, Shaker R. Dakhil, MD, Robert Dalton, MD, Stephen P Kahanic, MD, John W Kugler, MD, Philip J Stella, MD, Kendrith M Rowland, Jr., MD, Paul J Novotny, MS, Jeff A Sloan, PhD, Charles L Loprinzi, MD

Blood (2009) 114 (22): 630.

https://doi.org/10.1182/blood.V114.22.630.630

Published: 2009

Journal Articles

A Phase 2 Dose Regimen Optimization Study of Three Schedules of Voreloxin as Single Agent Therapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.

Farhad Ravandi, MD, Hagop M. Kantarjian, MD, Larry D. Cripe, Michael Maris, MD, Maureen Cooper, MD, Shaker R. Dakhil, MD, Richard M Stone, MD, Francesco Turturro, MD, Tianling Chen, MD, MSc, Kristi Mahadocon, Judith Fox, Craig Berman, Glenn C Michelson, MD, Robert K Stuart

Blood (2009) 114 (22): 1037.

https://doi.org/10.1182/blood.V114.22.1037.1037

Published: 2009

Journal Articles

Phase II Study of Rituximab and Cladribine (2-CDA) in Newly Diagnosed Mantle Cell Lymphoma (MCL) (N0189).

David James Inwards, MD, David W. Hillman, Paul A. Fishkin, MD, William L. White, MD, Roscoe F. Morton, MD, Shaker R. Dakhil, MD, Daniel A. Nikcevich, MD,PhD, Donald B. Wender, MD, Tom R. Fitch, MD, Paul J. Kurtin, MD

Blood (2006) 108 (11): 2746.

https://doi.org/10.1182/blood.V108.11.2746.2746

Published: 2006

Journal Articles

Phase 2 Study of Bortezomib Weekly or Twice Weekly Plus Rituximab in Patients with Follicular (FL) or Marginal Zone (MZL) Lymphoma: Final Results.

Sven De Vos, MD, PhD, Shaker R. Dakhil, MD, FACP, Peter McLaughlin, Mansoor N. Saleh, MD, Robert Belt, MD, Christopher Flowers, MD, Charles Holladay, MD, Mark Knapp, MD, Anthony Boral, MD, PhD, Tracy Zhang, MS, Andre Goy, MD

Blood (2006) 108 (11): 694.

https://doi.org/10.1182/blood.V108.11.694.694

Published: 2006

Journal Articles

Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase

Alan F. List, Kenneth J. Kopecky, Cheryl L. Willman, David R. Head, Marilyn L. Slovak, Dan Douer, Shaker R. Dakhil, Frederick R. Appelbaum

Blood (2002) 100 (5): 1910–1912.

https://doi.org/10.1182/blood.V100.5.1910.h81702001910_1910_1912

Published: 2002

NARROW

Cardiovascular and Metabolic Risk in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving First-Line BCR-ABL1 Tyrosine Kinase Inhibitors in the United States: Baseline and Six-Month Follow-up Results from a Prospective Real-World Observational Study

Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)

Management of Mucositis with the Use of Leucovorin As Adjunct to Pralatrexate in Treatment of Peripheral T-Cell Lymphomas (PTCL) — Results from a Prospective Multicenter Phase 2 Clinical Trial

Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naïve & Relapsed (Rel)/Refractory (Ref) Patients

Multiple Myeloma On Top of Chronic Myelogenous Leukemia

Differences in Outcomes in Males and Females with Diffuse Large B-Cell Lymphoma with Induction Rituximab and Follicular Lymphoma Treated with Maintenance Rituximab

Final Results of a Single Arm Phase III Multicenter, Open-Label Study of Rituximab Administered by Faster Infusion in Patients with Previously Untreated Diffuse Large-B Cell (DLBCL) or Follicular Non-Hodgkin's Lymphoma (FL)

A Randomized Comparison of Standard Weekly Epoetin Alfa to Every-3-Week Epoetin Alfa and Every-3-Week Darbepoetin Alfa: A Study of the Mayo Clinic Cancer Research Consortium (MCCRC).

A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation On the Erythropoietic Response to Darbepoetin Alfa for Patients with Chemotherapy-Associated Anemia: A Study of the Mayo Clinic Cancer Research Consortium (MCCRC).

A Phase 2 Dose Regimen Optimization Study of Three Schedules of Voreloxin as Single Agent Therapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.

Phase II Study of Rituximab and Cladribine (2-CDA) in Newly Diagnosed Mantle Cell Lymphoma (MCL) (N0189).

Phase 2 Study of Bortezomib Weekly or Twice Weekly Plus Rituximab in Patients with Follicular (FL) or Marginal Zone (MZL) Lymphoma: Final Results.

Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only